You are here

Johannes Czernin, MD
 - Johannes Czernin, MD
Molecular Imaging

Initial Results from National Oncologic PET Registry (NOPR) have been published recently in the Journal of Clinical Oncology. The results provide impressive evidence for the substantial impact of PET imaging across all cancers.

 - Johannes Czernin, MD
Molecular Imaging

This issue we are discussing several important topics in molecular imaging and medicine. One addresses the need for developing tools not only to monitor therapeutic responses, but also to stratify patients into the treatments that are most likely to result in significant responses. This concept can be applied not only to oncology, but also is highly relevant in patients with neurologic and cardiac diseases.

 - Johannes Czernin, MD
Molecular Imaging

This issue features several topics of critical importance in the field of imaging.

 - Johannes Czernin, MD (Portrait)
Molecular Imaging

This issue of Molecular Imaging Insight focuses on test accuracy, cost and outcomes—all very key topics in 2012.

 - Johannes Czernin, MD (Portrait)
Molecular Imaging

This issue provides discussions about potential risks associated with diagnostic tests in pediatric patients, PET probes for imaging neuroinflammation and neurodegenerative diseases, as well as emerging hybrid imaging technologies such as PET/MRI.

 - Johannes Czernin, MD (Portrait)
Molecular Imaging

Nuclear cardiology is changing to become an important application of molecular imaging.

 - Johannes Czernin, MD (Portrait)
Molecular Imaging

This issue highlights the emergence of PET/MR, which follows the introduction of SPECT/CT and PET/CT that have convincingly shown that multimodality imaging can result in significantly improved disease characterization.

 - Johannes Czernin, MD (Portrait)
Molecular Imaging

The cover story in this issue discusses the role of PET imaging for assessing therapeutic responses in cancer. Over the past 15 years, a large body of evidence has demonstrated that FDG-PET imaging is uniquely useful to assess treatment responses in cancer patients.

 - Johannes Czernin, MD (Portrait)
Molecular Imaging

PET imaging can play an invaluable role in monitoring the effects of cancer therapies. In my view, cancer therapies that do not achieve early reductions in FDG uptake cannot be effective.

 - Johannes Czernin, MD (Portrait)
Molecular Imaging

This issue provides updates on several important applications of molecular imaging. The cover story presents novel ideas to better identify patients who are at risk for or have coronary artery disease.